Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303
Benzinga Newsdesk 1 day ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment settingResults support the ongoing Phase
- With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting
- Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer
More on RVMD
FDA & biotech Benzinga
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug RegimenRevolution Medicines shares updated Phase 1/2 Rasonque data showing a 60.7% response rate and 76.6% 12-month survival in pancreatic cancer.

